Old Web
English
Sign In
Acemap
>
authorDetail
>
Esther De La Cuesta
Esther De La Cuesta
Bayer
Trk receptor
Cancer research
Medicine
Kinase
Receptor
3
Papers
3
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Discovery of a rare GKAP1-NTRK2 fusion in a pediatric low-grade glioma, leading to targeted treatment with TRK-inhibitor larotrectinib.
2021
Cancer Biology & Therapy
Lily Deland
Simon Keane
Thomas Olsson Bontell
Helene Sjögren
Henrik Fagman
Ingrid Øra
Esther De La Cuesta
Magnus Tisell
Jonas A. Nilsson
Katarina Ejeskär
Magnus Sabel
Frida Abel
Show All
Source
Cite
Save
Citations (0)
Impact of Disease Evolution on Efficacy Outcomes From Larotrectinib in Patients With Locally Advanced or Metastatic Tropomyosin Receptor Kinase Fusion–Positive Solid Tumors
2021
Carsten Bokemeyer
Gilles Vassal
Antoine Italiano
Esther De La Cuesta
Florian Hiemeyer
Marc Fellous
Marisca Marian
Show All
Source
Cite
Save
Citations (0)
A newborn with a large NTRK fusion positive infantile fibrosarcoma successfully treated with larotrectinib.
2020
Pediatric Blood & Cancer
Kenneth J. Caldwell
Esther De La Cuesta
Cara E. Morin
Alberto S. Pappo
Sara Helmig
Show All
Source
Cite
Save
Citations (3)
1